{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:27:13Z","timestamp":1792373233585,"version":"4.4.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40122-025-00771-1","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:45:13Z","timestamp":1758271513000},"page":"1647-1686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Calcium Channel \u03b12\u03b4 Ligands Mirogabalin, Pregabalin, and Gabapentin: Advancements in Diabetic Peripheral Neuropathic Pain Therapeutics"],"prefix":"10.1007","volume":"14","author":[{"given":"Yiming","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"771_CR1","unstructured":"International Diabetes Federation (IDF). IDF Diabetes Atlas 11th Edition [Internet]. 2025. Available from: https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/. Accessed 20 July 2025."},{"key":"771_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/s-2002-19988","volume":"110","author":"A Liebl","year":"2002","unstructured":"Liebl A, Neiss A, Spannheimer A, Reitberger U, Wieseler B, Stammer H, et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany \u2013 Results from the CODE-2 study. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc. 2002;110:10\u20136.","journal-title":"Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc"},{"key":"771_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12955-014-0171-7","volume":"12","author":"V Dermanovic Dobrota","year":"2014","unstructured":"Dermanovic Dobrota V, Hrabac P, Skegro D, Smiljanic R, Dobrota S, Prkacin I, et al. The impact of neuropathic pain and other comorbidities on the quality of life in patients with diabetes. Health Qual Life Outcomes. 2014;12:171.","journal-title":"Health Qual Life Outcomes"},{"key":"771_CR4","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.2337\/dc12-1964","volume":"36","author":"S Tesfaye","year":"2013","unstructured":"Tesfaye S, Boulton AJM, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 2013;36:2456\u201365.","journal-title":"Diabetes Care"},{"key":"771_CR5","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2337\/dc10-1303","volume":"33","author":"S Tesfaye","year":"2010","unstructured":"Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285\u201393.","journal-title":"Diabetes Care"},{"key":"771_CR6","doi-asserted-by":"crossref","unstructured":"Pop-Busui R, Ang L, Boulton AJM, Feldman EL, Marcus RL, Mizokami-Stout K, et al. Diagnosis and treatment of painful diabetic peripheral neuropathy [Internet]. Arlington (VA): American Diabetes Association; 2022 [cited 2023 Dec 20]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK580224\/.","DOI":"10.2337\/db2022-01"},{"key":"771_CR7","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1093\/brain\/awab079","volume":"144","author":"TS Jensen","year":"2021","unstructured":"Jensen TS, Karlsson P, Gylfadottir SS, Andersen ST, Bennett DL, Tankisi H, et al. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain. 2021;144:1632\u201345.","journal-title":"Brain"},{"key":"771_CR8","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(04)16508-2","volume":"363","author":"JD England","year":"2004","unstructured":"England JD, Asbury AK. Peripheral neuropathy. Lancet. 2004;363:2151\u201361.","journal-title":"Lancet"},{"key":"771_CR9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1474-4422(14)70102-4","volume":"13","author":"TS Jensen","year":"2014","unstructured":"Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. 2014;13:924\u201335.","journal-title":"Lancet Neurol"},{"key":"771_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","volume":"160","author":"J Scholz","year":"2019","unstructured":"Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett MI, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160:53\u20139.","journal-title":"Pain"},{"key":"771_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110602","volume":"198","author":"C Li","year":"2023","unstructured":"Li C, Wang W, Ji Q, Ran X, Kuang H, Yu X, et al. Prevalence of painful diabetic peripheral neuropathy in type 2 diabetes mellitus and diabetic peripheral neuropathy: a nationwide cross-sectional study in mainland China. Diabetes Res Clin Pract. 2023;198: 110602.","journal-title":"Diabetes Res Clin Pract"},{"key":"771_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1097\/j.pain.0000000000000491","volume":"157","author":"AC Themistocleous","year":"2016","unstructured":"Themistocleous AC, Ramirez JD, Shillo PR, Lees JG, Selvarajah D, Orengo C, et al. The pain in neuropathy study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. Pain. 2016;157:1132\u201345.","journal-title":"Pain"},{"key":"771_CR13","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1097\/j.pain.0000000000001034","volume":"158","author":"J Raputova","year":"2017","unstructured":"Raputova J, Srotova I, Vlckova E, Sommer C, \u00dc\u00e7eyler N, Birklein F, et al. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. Pain. 2017;158:2340\u201353.","journal-title":"Pain"},{"key":"771_CR14","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/j.1526-4637.2007.00349.x","volume":"8","author":"BE Cole","year":"2007","unstructured":"Cole BE. Diabetic peripheral neuropathic pain: recognition and management. Pain Med. 2007;8:S27-32.","journal-title":"Pain Med"},{"key":"771_CR15","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1007\/s12325-017-0536-5","volume":"34","author":"RAR Malik","year":"2017","unstructured":"Malik RAR, Aldinc E, Chan S. Perceptions of painful diabetic peripheral neuropathy in South-East Asia: results from patient and physician surveys. Adv Ther. 2017;34:1426\u201337.","journal-title":"Adv Ther"},{"key":"771_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/cells6040043","volume":"6","author":"A Schampel","year":"2017","unstructured":"Schampel A, Kuerten S. Danger: high voltage\u2014The role of voltage-gated calcium channels in central nervous system pathology. Cells. 2017;6:43.","journal-title":"Cells"},{"key":"771_CR17","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.16104.1","volume":"7","author":"AC Dolphin","year":"2018","unstructured":"Dolphin AC. Voltage-gated calcium channel \u03b1 2\u03b4 subunits: an assessment of proposed novel roles. F1000Res. 2018;7: F1000 Faculty Rev-1830.","journal-title":"F1000Res"},{"key":"771_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40265-020-01259-2","volume":"80","author":"U Alam","year":"2020","unstructured":"Alam U, Sloan G, Tesfaye S. Treating pain in diabetic neuropathy: current and developmental drugs. Drugs. 2020;80:363\u201384.","journal-title":"Drugs"},{"key":"771_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tips.2006.12.006","volume":"28","author":"DJ Dooley","year":"2007","unstructured":"Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28:75\u201382.","journal-title":"Trends Pharmacol Sci"},{"key":"771_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pain.2008.11.019","volume":"142","author":"CP Taylor","year":"2009","unstructured":"Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin\u2013calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain. 2009;142:13\u20136.","journal-title":"Pain"},{"key":"771_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/WNL.0000000000013038","volume":"98","author":"R Price","year":"2022","unstructured":"Price R, Smith D, Franklin G, Gronseth G, Pignone M, David WS, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN guideline subcommittee. Neurology. 2022;98:31\u201343.","journal-title":"Neurology"},{"key":"771_CR22","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.2337\/dc24-S012","volume":"47","author":"NA ElSayed","year":"2024","unstructured":"ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, American Diabetes Association Professional Practice Committee, et al. Retinopathy, neuropathy, and foot care: standards of care in diabetes\u20142024. Diabetes Care. 2024;47:S231\u201343.","journal-title":"Diabetes Care"},{"key":"771_CR23","first-page":"499","volume":"37","author":"L Shi","year":"2021","unstructured":"Shi L, Zhu D, Complications C. Expert consensus on diagnosis and treatment of diabetic neuropathy (2021 edition). Chin J Endocrinol Metab. 2021;37:499\u2013515.","journal-title":"Chin J Endocrinol Metab."},{"key":"771_CR24","first-page":"496","volume":"16","author":"L Shi","year":"2024","unstructured":"Shi L, Zhu D. National guidelines for the diagnosis and treatment of diabetic neuropathy in primary care (2024 edition). Chin J Diabetes Mellit. 2024;16:496\u2013511.","journal-title":"Chin J Diabetes Mellit"},{"key":"771_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.699731\/full","author":"W Cui","year":"2021","unstructured":"Cui W, Wu H, Yu X, Song T, Xu X, Xu F. The calcium channel \u03b12\u03b41 subunit: interactional targets in primary sensory neurons and role in neuropathic pain. Front Cell Neurosci [Internet]. 2021. https:\/\/doi.org\/10.3389\/fncel.2021.699731\/full.","journal-title":"Front Cell Neurosci [Internet]"},{"key":"771_CR26","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1074\/jbc.271.10.5768","volume":"271","author":"NS Gee","year":"1996","unstructured":"Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271:5768\u201376.","journal-title":"J Biol Chem"},{"key":"771_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00232-001-0072-7","volume":"184","author":"HC Gong","year":"2001","unstructured":"Gong HC, Hang J, Kohler W, Li L, Su TZ. Tissue-specific expression and gabapentin-binding properties of calcium channel alpha2delta subunit subtypes. J Membr Biol. 2001;184:35\u201343.","journal-title":"J Membr Biol"},{"key":"771_CR28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/mus.22092","volume":"43","author":"V Bril","year":"2011","unstructured":"Bril V, England J, Franklin G, Backonja M. Evidencebased guideline: treatment of painful diabetic neuropathy\u2013report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation. Muscle Nerve. 2011;43:910\u20137.","journal-title":"Muscle Nerve"},{"key":"771_CR29","volume-title":"LYRICA (Pregabalin) capsules","author":"Pfizer","year":"2013","unstructured":"Pfizer. LYRICA (Pregabalin) capsules. New York: Pfizer Pharmaceuticals; 2013."},{"key":"771_CR30","unstructured":"Japan Pain Clinic Society. Neuropathic pain pharmacology guidelines, revised 2nd edition, supplementary edition [Internet]. 2024 [cited 2024 Feb 12]. Available from: https:\/\/www.jspc.gr.jp\/Contents\/public\/kaiin_guideline09.html."},{"key":"771_CR31","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1172\/JCI43766","volume":"120","author":"MH Ossipov","year":"2010","unstructured":"Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest. 2010;120:3779\u201387.","journal-title":"J Clin Invest"},{"key":"771_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121803","volume":"326","author":"M Adzic","year":"2023","unstructured":"Adzic M, Lukic I, Mitic M, Glavonic E, Dragicevic N, Ivkovic S. Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine. Life Sci. 2023;326: 121803.","journal-title":"Life Sci"},{"key":"771_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"R Pop-Busui","year":"2016","unstructured":"Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2016;40:136\u201354.","journal-title":"Diabetes Care"},{"key":"771_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41398-025-03289-4","volume":"15","author":"S Meshkat","year":"2025","unstructured":"Meshkat S, Duffy FS, Tassone KV, Lin Q, Pang YMH, Jung H, et al. Increased odds of metabolic syndrome among adults with depressive symptoms or antidepressant use. Transl Psychiatry. 2025;15:68.","journal-title":"Transl Psychiatry"},{"key":"771_CR35","unstructured":"EMA Europe. CYMBALTA (Duloxetine Delayed-Release Capsules) for Oral Use. Indianapolis, IN: Lilly USA LLC; 2012."},{"key":"771_CR36","unstructured":"EMA Europe. Cymbalta | European Medicines Agency [Internet]. 2024 [cited 2024 May 20]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cymbalta. . Accessed 20 May 2024."},{"key":"771_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","volume":"116","author":"DJ Goldstein","year":"2005","unstructured":"Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109\u201318.","journal-title":"Pain"},{"key":"771_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2337\/dc06-0947","volume":"30","author":"T Hardy","year":"2007","unstructured":"Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJM. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care. 2007;30:21\u20136.","journal-title":"Diabetes Care"},{"key":"771_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/jpm.2006.9.29","volume":"9","author":"J Raskin","year":"2006","unstructured":"Raskin J, Smith TR, Wong K, Pritchett YL, D\u2019Souza DN, Iyengar S, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med. 2006;9:29\u201340.","journal-title":"J Palliat Med"},{"key":"771_CR40","first-page":"346","volume":"6","author":"J Raskin","year":"2005","unstructured":"Raskin J, Pritchett YL, Wang F, D\u2019Souza DN, Waninger AL, Iyengar S, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med Malden Mass. 2005;6:346\u201356.","journal-title":"Pain Med Malden Mass"},{"key":"771_CR41","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","volume":"85","author":"RH Dworkin","year":"2010","unstructured":"Dworkin RH, O\u2019Connor AB, Audette J, Baron R, Gourlay GK, Haanp\u00e4\u00e4 ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85:S3-14.","journal-title":"Mayo Clin Proc"},{"key":"771_CR42","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, Haanp\u00e4\u00e4 M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113.","journal-title":"Eur J Neurol"},{"key":"771_CR43","unstructured":"Husein R, Depkes R, Soelistijo S. Global Guideline for Type 2 Diabetes. 2020. https:\/\/www.idf.org\/e-library\/guidelines\/79-global-guideline-for-type-2-diabetes. Accessed 19 Sept 2024."},{"key":"771_CR44","volume-title":"NUCYNTA ER (tapentadol) extended-release oral tablets","author":"Janssen Pharmaceuticals","year":"2013","unstructured":"Janssen Pharmaceuticals. NUCYNTA ER (tapentadol) extended-release oral tablets. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2013."},{"key":"771_CR45","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.semcdb.2006.09.002","volume":"17","author":"VK Gribkoff","year":"2006","unstructured":"Gribkoff VK. The role of voltage-gated calcium channels in pain and nociception. Semin Cell Dev Biol. 2006;17:555\u201364.","journal-title":"Semin Cell Dev Biol"},{"key":"771_CR46","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0006-291X(87)80188-2","volume":"147","author":"MM Hosey","year":"1987","unstructured":"Hosey MM, Barhanin J, Schmid A, Vandaele S, Ptasienski J, O\u2019Callahan C, et al. Photoaffinity labelling and phosphorylation of a 165 kilodalton peptide associated with dihydropyridine and phenylalkylamine-sensitive calcium channels. Biochem Biophys Res Commun. 1987;147:1137\u201345.","journal-title":"Biochem Biophys Res Commun"},{"key":"771_CR47","doi-asserted-by":"publisher","first-page":"7943","DOI":"10.1016\/S0021-9258(18)47507-2","volume":"262","author":"AT Leung","year":"1987","unstructured":"Leung AT, Imagawa T, Campbell KP. Structural characterization of the 1,4-dihydropyridine receptor of the voltage-dependent Ca2+ channel from rabbit skeletal muscle. Evidence for two distinct high molecular weight subunits. J Biol Chem. 1987;262:7943\u20136.","journal-title":"J Biol Chem"},{"key":"771_CR48","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev.cellbio.16.1.521","volume":"16","author":"WA Catterall","year":"2000","unstructured":"Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521\u201355.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"771_CR49","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1126\/science.2458626","volume":"241","author":"SB Ellis","year":"1988","unstructured":"Ellis SB, Williams ME, Ways NR, Brenner R, Sharp AH, Leung AT, et al. Sequence and expression of mRNAs encoding the alpha 1 and alpha 2 subunits of a DHP-sensitive calcium channel. Science. 1988;241:1661\u20134.","journal-title":"Science"},{"key":"771_CR50","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1523\/JNEUROSCI.21-16-06095.2001","volume":"21","author":"J Barclay","year":"2001","unstructured":"Barclay J, Balaguero N, Mione M, Ackerman SL, Letts VA, Brodbeck J, et al. Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the Cacna2d2 gene and decreased calcium channel current in cerebellar Purkinje cells. J Neurosci Off J Soc Neurosci. 2001;21:6095\u2013104.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"771_CR51","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1523\/JNEUROSCI.19-02-00684.1999","volume":"19","author":"N Klugbauer","year":"1999","unstructured":"Klugbauer N, Lacinov\u00e1 L, Marais E, Hobom M, Hofmann F. Molecular diversity of the calcium channel \u03b12\u03b4 subunit. J Neurosci. 1999;19:684\u201391.","journal-title":"J Neurosci"},{"key":"771_CR52","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1124\/mol.62.3.485","volume":"62","author":"N Qin","year":"2002","unstructured":"Qin N, Yagel S, Momplaisir M-L, Codd EE, D\u2019Andrea MR. Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. Mol Pharmacol. 2002;62:485\u201396.","journal-title":"Mol Pharmacol"},{"key":"771_CR53","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1086\/508944","volume":"79","author":"KA Wycisk","year":"2006","unstructured":"Wycisk KA, Zeitz C, Feil S, Wittmer M, Forster U, Neidhardt J, et al. Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy. Am J Hum Genet. 2006;79:973\u20137.","journal-title":"Am J Hum Genet"},{"key":"771_CR54","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1124\/pr.57.4.5","volume":"57","author":"WA Catterall","year":"2005","unstructured":"Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev. 2005;57:411\u201325.","journal-title":"Pharmacol Rev"},{"key":"771_CR55","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.neuron.2008.09.005","volume":"59","author":"WA Catterall","year":"2008","unstructured":"Catterall WA, Few AP. Calcium channel regulation and presynaptic plasticity. Neuron. 2008;59:882\u2013901.","journal-title":"Neuron"},{"key":"771_CR56","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0006-8993(95)01447-0","volume":"712","author":"AR Evans","year":"1996","unstructured":"Evans AR, Nicol GD, Vasko MR. Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons. Brain Res. 1996;712:265\u201373.","journal-title":"Brain Res"},{"key":"771_CR57","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0304-3940(92)90039-A","volume":"136","author":"P Santicioli","year":"1992","unstructured":"Santicioli P, Bianco ED, Tramontana M, Geppetti P, Maggi CA. Release of calcitonin gene-related peptide like-immunoreactivity induced by electrical field stimulation from rat spinal afferents is mediated by conotoxin-sensitive calcium channels. Neurosci Lett. 1992;136:161\u20134.","journal-title":"Neurosci Lett"},{"key":"771_CR58","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/0006-8993(94)90398-0","volume":"653","author":"K Gohil","year":"1994","unstructured":"Gohil K, Bell JR, Ramachandran J, Miljanich GP. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res. 1994;653:258\u201366.","journal-title":"Brain Res"},{"key":"771_CR59","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/0896-6273(92)90069-P","volume":"9","author":"RE Westenbroek","year":"1992","unstructured":"Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron. 1992;9:1099\u2013115.","journal-title":"Neuron"},{"key":"771_CR60","doi-asserted-by":"publisher","first-page":"e774","DOI":"10.1097\/j.pain.0000000000002465","volume":"163","author":"JE Hartung","year":"2022","unstructured":"Hartung JE, Moy JK, Loeza-Alcocer E, Nagarajan V, Jostock R, Christoph T, et al. Voltage-gated calcium currents in human dorsal root ganglion neurons. Pain. 2022;163:e774\u201385.","journal-title":"Pain"},{"key":"771_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.brainres.2004.07.066","volume":"1024","author":"M Murakami","year":"2004","unstructured":"Murakami M, Nakagawasai O, Suzuki T, Mobarakeh II, Sakurada Y, Murata A, et al. Antinociceptive effect of different types of calcium channel inhibitors and the distribution of various calcium channel alpha 1 subunits in the dorsal horn of spinal cord in mice. Brain Res. 2004;1024:122\u20139.","journal-title":"Brain Res"},{"key":"771_CR62","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1602\/neurorx.2.4.662","volume":"2","author":"TP Snutch","year":"2005","unstructured":"Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx. 2005;2:662\u201370.","journal-title":"NeuroRx"},{"key":"771_CR63","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1523\/JNEUROSCI.0356-09.2009","volume":"29","author":"CS Bauer","year":"2009","unstructured":"Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci Off J Soc Neurosci. 2009;29:4076\u201388.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"771_CR64","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1113\/JP272262","volume":"594","author":"AC Dolphin","year":"2016","unstructured":"Dolphin AC. Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. J Physiol. 2016;594:5369\u201390.","journal-title":"J Physiol"},{"key":"771_CR65","doi-asserted-by":"publisher","first-page":"8494","DOI":"10.1523\/JNEUROSCI.2982-04.2004","volume":"24","author":"C-Y Li","year":"2004","unstructured":"Li C-Y, Song Y-H, Higuera ES, Luo ZD. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci Off J Soc Neurosci. 2004;24:8494\u20139.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"771_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0169-328X(01)00188-7","volume":"95","author":"RA Newton","year":"2001","unstructured":"Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res. 2001;95:1\u20138.","journal-title":"Brain Res Mol Brain Res"},{"key":"771_CR67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pain.2006.04.022","volume":"125","author":"C-Y Li","year":"2006","unstructured":"Li C-Y, Zhang X-L, Matthews EA, Li K-W, Kurwa A, Boroujerdi A, et al. Calcium channel \u03b12\u03b41 subunit mediates spinal hyperexcitability in pain modulation. Pain. 2006;125:20.","journal-title":"Pain"},{"key":"771_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.205","volume":"4","author":"R Patel","year":"2016","unstructured":"Patel R, Dickenson A. Mechanisms of the gabapentinoids and \u03b1 2 \u03b4-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016;4: e00205.","journal-title":"Pharmacol Res Perspect"},{"key":"771_CR69","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.pain.2010.12.014","volume":"152","author":"A Boroujerdi","year":"2011","unstructured":"Boroujerdi A, Zeng J, Sharp K, Kim D, Steward O, Luo DZ. Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. Pain. 2011;152:649\u201355.","journal-title":"Pain"},{"key":"771_CR70","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1074\/jbc.M114.548990","volume":"289","author":"K-W Li","year":"2014","unstructured":"Li K-W, Yu YP, Zhou C, Kim D-S, Lin B, Sharp K, et al. Calcium channel \u03b12\u03b41 proteins mediate trigeminal neuropathic pain states associated with aberrant excitatory synaptogenesis. J Biol Chem. 2014;289:7025\u201337.","journal-title":"J Biol Chem"},{"key":"771_CR71","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1523\/JNEUROSCI.21-06-01868.2001","volume":"21","author":"ZD Luo","year":"2001","unstructured":"Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci Off J Soc Neurosci. 2001;21:1868\u201375.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"771_CR72","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/bbrc.2001.5943","volume":"289","author":"SP Yusaf","year":"2001","unstructured":"Yusaf SP, Goodman J, Gonzalez IM, Bramwell S, Pinnock RD, Dixon AK, et al. Streptozocin-induced neuropathy is associated with altered expression of voltage-gated calcium channel subunit mRNAs in rat dorsal root ganglion neurones. Biochem Biophys Res Commun. 2001;289:402\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"771_CR73","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.bja.2018.02.066","volume":"120","author":"M Chincholkar","year":"2018","unstructured":"Chincholkar M. Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review. Br J Anaesth. 2018;120:1315\u201334.","journal-title":"Br J Anaesth"},{"key":"771_CR74","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1124\/jpet.102.041574","volume":"303","author":"ZD Luo","year":"2002","unstructured":"Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song Y-H, Svensson CI, et al. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002;303:1199\u2013205.","journal-title":"J Pharmacol Exp Ther"},{"key":"771_CR75","doi-asserted-by":"publisher","first-page":"8748","DOI":"10.1523\/JNEUROSCI.2764-06.2006","volume":"26","author":"A Davies","year":"2006","unstructured":"Davies A, Douglas L, Hendrich J, Wratten J, Tran Van Minh A, Foucault I, et al. The calcium channel alpha2delta-2 subunit partitions with CaV.1 into lipid rafts in cerebellum: implications for localization and function. J Neurosci Off J Soc Neurosci. 2006;26:8748\u201357.","journal-title":"J Neurosci Off J Soc Neurosci."},{"key":"771_CR76","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.0409066103","volume":"103","author":"MJ Field","year":"2006","unstructured":"Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su T-Z, et al. Identification of the \u03b12-\u03b4-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006;103:17537\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"771_CR77","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/ALN.0b013e31821f6545","volume":"115","author":"K Bannister","year":"2011","unstructured":"Bannister K, Sikandar S, Bauer CS, Dolphin AC, Porreca F, Dickenson AH. Pregabalin suppresses spinal neuronal hyperexcitability and visceral hypersensitivity in the absence of peripheral pathophysiology. Anesthesiology. 2011;115:144\u201352.","journal-title":"Anesthesiology"},{"key":"771_CR78","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000087656","volume":"14","author":"R Suzuki","year":"2005","unstructured":"Suzuki R, Dickenson A. Spinal and supraspinal contributions to central sensitization in peripheral neuropathy. Neurosignals. 2005;14:175\u201381.","journal-title":"Neurosignals"},{"key":"771_CR79","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neures.2023.11.003","volume":"202","author":"H Yanagimura","year":"2024","unstructured":"Yanagimura H, Sasaki M, Baba H, Kamiya Y. Influence of the descending pain-inhibiting serotonergic pathway on the antihyperalgesic effect of gabapentin in neuropathic pain model rats. Neurosci Res. 2024;202:20\u20139.","journal-title":"Neurosci Res"},{"key":"771_CR80","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.neuropharm.2014.01.040","volume":"81","author":"T Suto","year":"2014","unstructured":"Suto T, Severino AL, Eisenach JC, Hayashida K. Gabapentin increases extracellular glutamatergic level in the locus coeruleus via astroglial glutamate transporter-dependent mechanisms. Neuropharmacology. 2014;81:95\u2013100.","journal-title":"Neuropharmacology"},{"key":"771_CR81","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.celrep.2018.02.021","volume":"22","author":"J Chen","year":"2018","unstructured":"Chen J, Li L, Chen S-R, Chen H, Xie J-D, Sirrieh RE, et al. The \u03b12\u03b4-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions. Cell Rep. 2018;22:2307\u201321.","journal-title":"Cell Rep"},{"key":"771_CR82","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.neulet.2016.10.053","volume":"636","author":"E Kato","year":"2017","unstructured":"Kato E, Matsuzawa R, Kobayashi S, Fukushima T, Maekawa M, Hori Y. Effects of pregabalin on spinal d-serine content and NMDA receptor-mediated synaptic transmission in mice with neuropathic pain. Neurosci Lett. 2017;636:270\u20135.","journal-title":"Neurosci Lett"},{"key":"771_CR83","doi-asserted-by":"publisher","DOI":"10.5812\/aapm.28968","volume":"5","author":"M-S Meymandi","year":"2015","unstructured":"Meymandi M-S, Keyhanfar F, Yazdanpanah O, Heravi G. The role of NMDARs ligands on antinociceptive effects of pregabalin in the tail flick test. Anesthesiol Pain Med. 2015;5: e28968.","journal-title":"Anesthesiol Pain Med"},{"key":"771_CR84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jphs.2021.01.002","volume":"146","author":"M Oyama","year":"2021","unstructured":"Oyama M, Watanabe S, Iwai T, Tanabe M. Mirogabalin activates the descending noradrenergic system by binding to the \u03b12\u03b4-1 subunit of voltage-gated Ca2+ channels to generate analgesic effects. J Pharmacol Sci. 2021;146:33\u20139.","journal-title":"J Pharmacol Sci"},{"key":"771_CR85","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bbi.2021.04.007","volume":"95","author":"KA Ahmad","year":"2021","unstructured":"Ahmad KA, Shoaib RM, Ahsan MZ, Deng M-Y, Ma L, Apryani E, et al. Microglial IL-10 and \u03b2-endorphin expression mediates gabapentinoids antineuropathic pain. Brain Behav Immun. 2021;95:344\u201361.","journal-title":"Brain Behav Immun"},{"key":"771_CR86","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/ph15010088","volume":"15","author":"R Zaj\u0105czkowska","year":"2022","unstructured":"Zaj\u0105czkowska R, Rojewska E, Ciechanowska A, Pawlik K, Ciapa\u0142a K, Kocot-K\u0119pska M, et al. Mirogabalin decreases pain-like behaviours and improves opioid and ketamine antinociception in a mouse model of neuropathic pain. Pharmaceuticals. 2022;15:88.","journal-title":"Pharmaceuticals"},{"key":"771_CR87","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0968-0004(00)01672-8","volume":"25","author":"V Anantharaman","year":"2000","unstructured":"Anantharaman V, Aravind L. Cache \u2013 A signaling domain common to animal Ca2+-channel subunits and a class of prokaryotic chemotaxis receptors. Trends Biochem Sci. 2000;25:535\u20137.","journal-title":"Trends Biochem Sci"},{"key":"771_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/19336950.2023.2167563","volume":"17","author":"KM Page","year":"2023","unstructured":"Page KM, Gumerov VM, Dahimene S, Zhulin IB, Dolphin AC. The importance of cache domains in \u03b12\u03b4 proteins and the basis for their gabapentinoid selectivity. Channels (Austin). 2023;17: 2167563.","journal-title":"Channels (Austin)"},{"key":"771_CR89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2110415119","volume":"119","author":"VM Gumerov","year":"2022","unstructured":"Gumerov VM, Andrianova EP, Matilla MA, Page KM, Monteagudo-Cascales E, Dolphin AC, et al. Amino acid sensor conserved from bacteria to humans. Proc Natl Acad Sci USA. 2022;119: e2110415119.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Pt 2","key":"771_CR90","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1042\/bj3420313","volume":"342","author":"M Wang","year":"1999","unstructured":"Wang M, Offord J, Oxender DL, Su TZ. Structural requirement of the calcium-channel subunit alpha2delta for gabapentin binding. Biochem J. 1999;342(Pt 2):313\u201320.","journal-title":"Biochem J"},{"key":"771_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168049","volume":"435","author":"D Kozai","year":"2023","unstructured":"Kozai D, Numoto N, Nishikawa K, Kamegawa A, Kawasaki S, Hiroaki Y, et al. Recognition mechanism of a novel gabapentinoid drug, Mirogabalin, for recombinant human \u03b12\u03b41, a voltage-gated calcium channel subunit. J Mol Biol. 2023;435: 168049.","journal-title":"J Mol Biol"},{"key":"771_CR92","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fncel.2020.00083","volume":"14","author":"SRA Alles","year":"2020","unstructured":"Alles SRA, Cain SM, Snutch TP. Pregabalin as a pain therapeutic: beyond calcium channels. Front Cell Neurosci. 2020;14:83.","journal-title":"Front Cell Neurosci"},{"key":"771_CR93","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1124\/mol.59.5.1243","volume":"59","author":"E Marais","year":"2001","unstructured":"Marais E, Klugbauer N, Hofmann F. Calcium channel alpha(2)delta subunits-structure and Gabapentin binding. Mol Pharmacol. 2001;59:1243\u20138.","journal-title":"Mol Pharmacol"},{"key":"771_CR94","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejphar.2011.05.054","volume":"667","author":"Z Li","year":"2011","unstructured":"Li Z, Taylor CP, Weber M, Piechan J, Prior F, Bian F, et al. Pregabalin is a potent and selective ligand for \u03b1(2)\u03b4-1 and \u03b1(2)\u03b4-2 calcium channel subunits. Eur J Pharmacol. 2011;667:80\u201390.","journal-title":"Eur J Pharmacol"},{"key":"771_CR95","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainres.2005.12.084","volume":"1075","author":"F Bian","year":"2006","unstructured":"Bian F, Li Z, Offord J, Davis MD, McCormick J, Taylor CP, et al. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 2006;1075:68\u201380.","journal-title":"Brain Res"},{"issue":"56","key":"771_CR96","first-page":"135","volume":"2020","author":"J Burgess","year":"1998","unstructured":"Burgess J, Javed S, Frank B, Malik RA, Alam U. Mirogabalin besylate in the treatment of neuropathic pain. Drugs Today Barc Spain. 1998;2020(56):135\u201349.","journal-title":"Drugs Today Barc Spain"},{"key":"771_CR97","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, et al. Binding characteristics and analgesic effects of Mirogabalin, a novel ligand for the \u03b12\u03b4 subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018;365:573\u201382.","journal-title":"J Pharmacol Exp Ther"},{"key":"771_CR98","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1080\/14656566.2021.1958780","volume":"22","author":"J Kato","year":"2021","unstructured":"Kato J, Inoue T, Yokoyama M, Kuroha M. A review of a new voltage-gated Ca2+ channel \u03b12\u03b4 ligand, mirogabalin, for the treatment of peripheral neuropathic pain. Expert Opin Pharmacother. 2021;22:2311\u201322.","journal-title":"Expert Opin Pharmacother"},{"key":"771_CR99","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","volume":"179","author":"CW Goodman","year":"2019","unstructured":"Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med. 2019;179:695\u2013701.","journal-title":"JAMA Intern Med"},{"key":"771_CR100","unstructured":"EMA Europe. EMA - Committee for Medicinal Products for Human Use (CHMP). Referral opinion pursuant to article 30 of council directive 2001\/83\/EC for Neurontin and associated names. 2006."},{"key":"771_CR101","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1272\/jnms.84.258","volume":"84","author":"R Masuda","year":"2017","unstructured":"Masuda R, Ajimi J, Murata T. Pharmacotherapy for neuropathic pain in Japan. J Nippon Med Sch. 2017;84:258\u201367.","journal-title":"J Nippon Med Sch"},{"key":"771_CR102","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/jnnp.66.2.251","volume":"66","author":"KC Gorson","year":"1999","unstructured":"Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry. 1999;66:251\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"771_CR103","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/papr.12014","volume":"13","author":"R Rauck","year":"2013","unstructured":"Rauck R, Makumi CW, Schwartz S, Graff O, Meno-Tetang G, Bell CF, et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract. 2013;13:485\u201396.","journal-title":"Pain Pract"},{"key":"771_CR104","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.diabres.2012.03.010","volume":"97","author":"D Sandercock","year":"2012","unstructured":"Sandercock D, Cramer M, Biton V, Cowles VE. A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Res Clin Pract. 2012;97:438\u201345.","journal-title":"Diabetes Res Clin Pract"},{"key":"771_CR105","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","volume":"280","author":"M Backonja","year":"1998","unstructured":"Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitusa randomized controlled trial. JAMA. 1998;280:1831\u20136.","journal-title":"JAMA"},{"key":"771_CR106","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0304-3959(02)00255-5","volume":"99","author":"MG Serpell","year":"2002","unstructured":"Serpell MG, Group NPS. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557.","journal-title":"Pain"},{"key":"771_CR107","first-page":"CD007938","volume":"2014","author":"RA Moore","year":"2014","unstructured":"Moore RA, Wiffen PJ, Derry S, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;2014:CD007938.","journal-title":"Cochrane Database Syst Rev"},{"key":"771_CR108","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14576","volume":"75","author":"Y-C Ko","year":"2021","unstructured":"Ko Y-C, Lee C-H, Wu C-S, Huang Y-J. Comparison of efficacy and safety of gabapentin and duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 2021;75: e14576.","journal-title":"Int J Clin Pract"},{"key":"771_CR109","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.2147\/DDDT.S185995","volume":"13","author":"N Majdinasab","year":"2019","unstructured":"Majdinasab N, Kaveyani H, Azizi M. A comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy. Drug Des Devel Ther. 2019;13:1985\u201392.","journal-title":"Drug Des Devel Ther"},{"key":"771_CR110","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/1753-0407.13148","volume":"13","author":"S Khasbage","year":"2021","unstructured":"Khasbage S, Shukla R, Sharma P, Singh S. A randomized control trial of duloxetine and gabapentin in painful diabetic neuropathy. J Diabetes. 2021;13:532\u201341.","journal-title":"J Diabetes"},{"key":"771_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2024.1513597\/full","author":"V Mayoral","year":"2025","unstructured":"Mayoral V, Galvez R, Ferr\u00e1ndiz M, Migu\u00e9ns V\u00e1zquez X, Cordero-Garc\u00eda C, Alc\u00e1ntara Montero A, et al. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety. Front Pain Res [Internet]. 2025. https:\/\/doi.org\/10.3389\/fpain.2024.1513597\/full.","journal-title":"Front Pain Res [Internet]"},{"key":"771_CR112","first-page":"CD007938","volume":"6","author":"PJ Wiffen","year":"2017","unstructured":"Wiffen PJ, Derry S, Bell RF, Rice AS, T\u00f6lle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938.","journal-title":"Cochrane Database Syst Rev"},{"key":"771_CR113","unstructured":"Pfizer. Pfizer\u2019s Lyrica\u00ae (Pregabalin) capsules CV receives approval for treatment of peripheral neuropathic pain in Japan | Pfizer [Internet]. 2010 [cited 2023 Dec 29]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_s_lyrica_pregabalin_capsules_cv_receives_approval_for_treatment_of_peripheral_neuropathic_pain_in_japan. Accessed 29 Dec 2023."},{"key":"771_CR114","unstructured":"Research and Markets. Investigation report on China\u2019s pregabalin market 2021\u20132025 [Internet]. 2024 [cited 2024 Jan 24]. Available from: https:\/\/www.researchandmarkets.com\/reports\/5393431\/investigation-report-on-chinas-pregabalin. Accessed 24 Jan 2024."},{"key":"771_CR115","unstructured":"EMA Europe. Pregabalin Pfizer | European Medicines Agency [Internet]. 2014 [cited 2024 Jan 23]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pregabalin-pfizer. Accessed 23 Jan 2024."},{"key":"771_CR116","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","volume":"63","author":"H Lesser","year":"2004","unstructured":"Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104\u201310.","journal-title":"Neurology"},{"key":"771_CR117","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","volume":"110","author":"J Rosenstock","year":"2004","unstructured":"Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628\u201338.","journal-title":"Pain"},{"key":"771_CR118","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","volume":"6","author":"RW Richter","year":"2005","unstructured":"Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253\u201360.","journal-title":"J Pain"},{"issue":"2","key":"771_CR119","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejpain.2007.05.003","volume":"12","author":"T T\u00f6lle","year":"2008","unstructured":"T\u00f6lle T, Freynhagen R, Versavel M, Trostmann U, Young JP. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12(2):203\u201313.","journal-title":"Eur J Pain"},{"key":"771_CR120","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/1753-0407.12585","volume":"10","author":"Y Mu","year":"2018","unstructured":"Mu Y, Liu X, Li Q, Chen K, Liu Y, Lv X, et al. Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: a randomized placebo-controlled trial. J Diabetes. 2018;10:256\u201365.","journal-title":"J Diabetes"},{"key":"771_CR121","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s11096-022-01528-y","volume":"45","author":"J Meaadi","year":"2023","unstructured":"Meaadi J, Obara I, Eldabe S, Nazar H. The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials. Int J Clin Pharm. 2023;45:556\u201365.","journal-title":"Int J Clin Pharm"},{"key":"771_CR122","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4103\/2230-8210.104137","volume":"16","author":"A Maseeh","year":"2012","unstructured":"Maseeh A, Srivastava A, Shah S, Vyasa B, Balaji M, Bhatter S, et al. A clinical study to compare the efficacy and safety of pregabalin sustained release formulation with pregabalin immediate release formulation in patients of diabetic peripheral neuropathic pain. Indian J Endocrinol Metab. 2012;16:477.","journal-title":"Indian J Endocrinol Metab"},{"key":"771_CR123","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/papr.12146","volume":"15","author":"R Freynhagen","year":"2015","unstructured":"Freynhagen R, Serpell M, Emir B, Whalen E, Parsons B, Clair A, et al. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2015;15:47\u201357.","journal-title":"Pain Pract"},{"key":"771_CR124","unstructured":"Taiwan Food and Drug Administration. Assessment report. TARLIGE\u00ae F.C. Tablets 15 mg [Internet]. Taiwan Food and Drug Administration; 2020 [cited 2025 Apr 13]. Available from: https:\/\/www.fda.gov.tw\/tc\/includes\/GetFile.ashx?id=f637368791343691781. Accessed 13 Apr 2025."},{"key":"771_CR125","unstructured":"Lee Han-soo. Daiichi Sankyo Korea wins expanded indication for neuropathic pain treatment Taleaje Korea Biomedical Review [Internet]. 2022. Available from: https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=14097. Accessed 23 May 2025."},{"key":"771_CR126","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/14656566.2021.2007239","volume":"23","author":"T Ushida","year":"2022","unstructured":"Ushida T, Yokoyama M, Shiosakai K, Saito K, Ibe S, Okuizumi K. A large-scale database study for the prescription status of a new voltage-gated Ca2+ channel \u03b12\u03b4 ligand, mirogabalin, in Japan. Expert Opin Pharmacother. 2022;23:273\u201383.","journal-title":"Expert Opin Pharmacother"},{"key":"771_CR127","doi-asserted-by":"publisher","first-page":"1491570","DOI":"10.3389\/fphar.2024.1491570","volume":"15","author":"F Yang","year":"2024","unstructured":"Yang F, Wang Y, Zhang M, Yu S. Mirogabalin as a novel calcium channel \u03b12\u03b4 ligand for the treatment of neuropathic pain: a review of clinical update. Front Pharmacol. 2024;15:1491570.","journal-title":"Front Pharmacol"},{"key":"771_CR128","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-019-01070-8","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Mirogabalin: first global approval. Drugs. 2019;79:463\u20138.","journal-title":"Drugs"},{"key":"771_CR129","doi-asserted-by":"publisher","first-page":"4893436","DOI":"10.1155\/2023\/4893436","volume":"2023","author":"H Tang","year":"2023","unstructured":"Tang H, Lu J, Duan Y, Li D. The clinical application and progress of mirogabalin on neuropathic pain as a novel selective gabapentinoids. Mediators Inflamm. 2023;2023:4893436.","journal-title":"Mediators Inflamm"},{"key":"771_CR130","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.2337\/dc14-1044","volume":"37","author":"A Vinik","year":"2014","unstructured":"Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-and active comparator\u2013controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37:3253\u201361.","journal-title":"Diabetes Care"},{"key":"771_CR131","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1093\/pm\/pnw342","volume":"18","author":"D Merante","year":"2017","unstructured":"Merante D, Rosenstock J, Sharma U, Feins K, Hsu C, Vinik A. Efficacy of mirogabalin (DS-5565) on patient-reported pain and sleep interference in patients with diabetic neuropathic pain: secondary outcomes of a phase II proof-of-concept study. Pain Med. 2017;18:2198\u2013207.","journal-title":"Pain Med"},{"key":"771_CR132","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jcph.567","volume":"56","author":"MM Hutmacher","year":"2016","unstructured":"Hutmacher MM, Frame B, Miller R, Truitt K, Merante D. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain. J Clin Pharmacol. 2016;56:67\u201377.","journal-title":"J Clin Pharmacol"},{"key":"771_CR133","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jdi.13013","volume":"10","author":"M Baba","year":"2019","unstructured":"Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019;10:1299\u2013306.","journal-title":"J Diabetes Investig"},{"key":"771_CR134","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40122-024-00617-2","volume":"13","author":"X Guo","year":"2024","unstructured":"Guo X, Yu Y, Zhang Y, Sun L, Li Y, Song B, et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled 14-week study of mirogabalin in Chinese patients with diabetic peripheral neuropathic pain. Pain Ther. 2024;13:937\u201352.","journal-title":"Pain Ther"},{"key":"771_CR135","doi-asserted-by":"crossref","unstructured":"Alyoubi R, Alshareef A, Aldughaither S, Aljaroudi A, Alabdulwahed A, Alduraibi F, et al. Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: a systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract [Internet]. 2021 [cited 2024 Jan 24];75. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32991782\/. Accessed 24 Jan 2024.","DOI":"10.1111\/ijcp.13744"},{"key":"771_CR136","first-page":"E1","volume":"24","author":"MM Asrar","year":"2021","unstructured":"Asrar MM, Kumari S, Sekhar BC, Bhansali A, Bansal D. Relative efficacy and safety of pharmacotherapeutic interventions for diabetic peripheral neuropathy: a systematic review and Bayesian network meta-analysis. Pain Physician. 2021;24:E1-14.","journal-title":"Pain Physician"},{"key":"771_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106777","volume":"197","author":"L-M Hong","year":"2024","unstructured":"Hong L-M, Liu J-M, Lin L, Huang C-C, Chen R, Lin W-W. Modeling an evaluation of the efficacy of the novel neuroanalgesic drug mirogabalin for diabetic peripheral neuropathic pain and postherpetic neuralgia therapy. Eur J Pharm Sci. 2024;197: 106777.","journal-title":"Eur J Pharm Sci"},{"key":"771_CR138","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40122-021-00255-y","volume":"10","author":"Y Kimura","year":"2021","unstructured":"Kimura Y, Yamaguchi S, Suzuki T, Kato J, Chiba S, Hirakawa N, et al. Switching from pregabalin to mirogabalin in patients with peripheral neuropathic pain: a multi-center, prospective, single-arm, open-label study (MIROP study). Pain Ther. 2021;10:711\u201327.","journal-title":"Pain Ther"},{"key":"771_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-020-01709-3","volume":"15","author":"T Tetsunaga","year":"2020","unstructured":"Tetsunaga T, Tetsunaga T, Nishida K, Misawa H, Takigawa T, Yamane K, et al. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study. J Orthop Surg Res. 2020;15: 191.","journal-title":"J Orthop Surg Res"},{"key":"771_CR140","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1177\/21925682211031185","volume":"13","author":"T Akazawa","year":"2023","unstructured":"Akazawa T, Inoue G, Tanaka M, Umehara T, Nagai T, Oshita Y, et al. Somnolence and dizziness during Mirogabalin treatment in patients with neuropathic pain related to lumbar disease who switched from pregabalin: a retrospective study. Glob Spine J. 2023;13:1319\u201324.","journal-title":"Glob Spine J"},{"key":"771_CR141","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40122-020-00156-6","volume":"9","author":"M Baba","year":"2020","unstructured":"Baba M, Kuroha M, Ohwada S, Murayama E, Matsui N. Results of mirogabalin treatment for diabetic peripheral neuropathic pain in Asian subjects: a phase 2, double-blind, randomized, placebo-controlled, study. Pain Ther. 2020;9:261\u201378.","journal-title":"Pain Ther"},{"key":"771_CR142","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/jdi.13178","volume":"11","author":"M Baba","year":"2020","unstructured":"Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig. 2020;11:693\u20138.","journal-title":"J Diabetes Investig"},{"key":"771_CR143","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.clinthera.2021.03.015","volume":"43","author":"J Kato","year":"2021","unstructured":"Kato J, Baba M, Kuroha M, Kakehi Y, Murayama E, Wasaki Y, et al. Safety and efficacy of mirogabalin for peripheral neuropathic pain: pooled analysis of two pivotal phase III studies. Clin Ther. 2021;43:822-835.e16.","journal-title":"Clin Ther"},{"key":"771_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1164536","author":"Q Pan","year":"2023","unstructured":"Pan Q, Fei S, Zhang L, Chen H, Luo J, Wang W, et al. How does diabetic peripheral neuropathy impact patients\u2019 burden of illness and the economy? A retrospective study in Beijing, China. Front Public Health [Internet]. 2023. https:\/\/doi.org\/10.3389\/fpubh.2023.1164536.","journal-title":"Front Public Health [Internet]"},{"key":"771_CR145","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3111\/13696998.2011.650773","volume":"15","author":"M Udall","year":"2012","unstructured":"Udall M, Harnett J, Mardekian J. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. J Med Econ. 2012;15:361\u201370.","journal-title":"J Med Econ"},{"key":"771_CR146","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vhri.2020.10.003","volume":"24","author":"E Gray","year":"2021","unstructured":"Gray E, Ye X, Wang Y-F, Wang S-J. Cost-effectiveness of mirogabalin for the treatment of diabetic peripheral neuropathic pain in Taiwan. Value Health Reg Issues. 2021;24:148\u201356.","journal-title":"Value Health Reg Issues"},{"key":"771_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.651","volume":"26","author":"Y He","year":"2023","unstructured":"He Y, Dai D, Vashi R, Xu H, Jin M, Feng Y, et al. EE350 cost-effectiveness of mirogabalin in treatment of diabetic peripheral neuropathic pain in mainland China. Value Health. 2023;26: S123.","journal-title":"Value Health"},{"key":"771_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.813210","volume":"12","author":"J Lian","year":"2022","unstructured":"Lian J, Wang H, Cui R, Zhang C, Fu J. Status of analgesic drugs and quality of life results for diabetic peripheral neuropathy in China. Front Endocrinol. 2022;12: 813210.","journal-title":"Front Endocrinol"},{"key":"771_CR149","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","volume":"400","author":"S Tesfaye","year":"2022","unstructured":"Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet. 2022;400:680\u201390.","journal-title":"Lancet"},{"key":"771_CR150","volume":"7","author":"D Turnbull","year":"2023","unstructured":"Turnbull D, Chugh R, Luck J. Systematic-narrative hybrid literature review: a strategy for integrating a concise methodology into a manuscript. Soc Sci Humanit Open. 2023;7: 100381.","journal-title":"Soc Sci Humanit Open"},{"key":"771_CR151","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2040622314552071","volume":"6","author":"S Javed","year":"2015","unstructured":"Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;6:15\u201328.","journal-title":"Ther Adv Chronic Dis"},{"key":"771_CR152","first-page":"311","volume":"37","author":"D Zhu","year":"2021","unstructured":"Zhu D, Society C. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020). Chin J Endocrinol Metab. 2021;37:311\u201398.","journal-title":"Chin J Endocrinol Metab."},{"key":"771_CR153","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/2049463720912496","volume":"14","author":"M Chincholkar","year":"2020","unstructured":"Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020;14:104\u201314.","journal-title":"Br J Pain"},{"key":"771_CR154","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.jpain.2005.01.114","volume":"6","author":"D Wesche","year":"2005","unstructured":"Wesche D, Bockbrader H. A pharmacokinetic comparison of pregabalin and gabapentin. J Pain. 2005;6:S29.","journal-title":"J Pain"},{"key":"771_CR155","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/2042098613505614","volume":"5","author":"C Toth","year":"2014","unstructured":"Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014;5:38\u201356.","journal-title":"Ther Adv Drug Saf"},{"key":"771_CR156","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.418","volume":"6","author":"K Brown","year":"2018","unstructured":"Brown K, Mendell J, Ohwada S, Hsu C, He L, Warren V, et al. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: results from phase 1 studies. Pharmacol Res Perspect. 2018;6: e00418.","journal-title":"Pharmacol Res Perspect"},{"key":"771_CR157","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cpdd.448","volume":"7","author":"M Jansen","year":"2018","unstructured":"Jansen M, Warrington S, Dishy V, Ohwada S, Johnson L, Brown K, et al. A randomized, placebo-controlled, double-blind study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeated doses of mirogabalin in healthy Asian volunteers. Clin Pharmacol Drug Dev. 2018;7:661\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"771_CR158","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/00498254.2021.1879408","volume":"51","author":"N Yamamura","year":"2021","unstructured":"Yamamura N, Mendel-Harary J, Brown K, Uchiyama M, Urasaki Y, Takahashi M, et al. Metabolism, excretion, and pharmacokinetics of [14C]mirogabalin, a novel \u03b12\u03b4 ligand, in healthy volunteers following oral administration. Xenobiotica. 2021;51:549\u201363.","journal-title":"Xenobiotica"},{"key":"771_CR159","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ejpain.2008.09.010","volume":"13","author":"R Wodarski","year":"2009","unstructured":"Wodarski R, Clark AK, Grist J, Marchand F, Malcangio M. Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats. Eur J Pain. 2009;13:807\u201311.","journal-title":"Eur J Pain"},{"key":"771_CR160","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.3390\/molecules28237862","volume":"28","author":"K Sa\u0142at","year":"2023","unstructured":"Sa\u0142at K, Zar\u0119ba P, Awtoniuk M, Sa\u0142at R. Naturally inspired molecules for neuropathic pain inhibition\u2014Effect of Mirogabalin and Cebranopadol on mechanical and thermal nociceptive threshold in mice. Molecules. 2023;28:7862.","journal-title":"Molecules"},{"key":"771_CR161","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1055\/a-1941-8907","volume":"73","author":"Y Domon","year":"2023","unstructured":"Domon Y, Kobayashi N, Kubota K, Kitano Y, Ueki H, Shimojo Y, et al. The novel gabapentinoid mirogabalin prevents upregulation of \u03b12\u03b4-1 subunit of voltage-gated calcium channels in spinal dorsal horn in a rat model of spinal nerve ligation. Drug Res. 2023;73:54\u201360.","journal-title":"Drug Res"},{"key":"771_CR162","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2377-8-33","volume":"8","author":"JC Arezzo","year":"2008","unstructured":"Arezzo JC, Rosenstock J, LaMoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg\/day for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.","journal-title":"BMC Neurol"},{"key":"771_CR163","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/AJP.0b013e31829ea1a1","volume":"30","author":"P Raskin","year":"2014","unstructured":"Raskin P, Cynthia H, Cory T. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy. Clin J Pain. 2014;30:379\u201390.","journal-title":"Clin J Pain"},{"key":"771_CR164","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1464-5491.2010.03152.x","volume":"28","author":"J Satoh","year":"2011","unstructured":"Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28:109\u201316.","journal-title":"Diabet Med"},{"key":"771_CR165","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/AJP.0000000000000198","volume":"31","author":"C Huffman","year":"2015","unstructured":"Huffman C, Stacey BR, Tuchman M, Burbridge C, Li C, Parsons B, et al. Efficacy and safety of pregabalin in the treatment of patients with painful diabetic peripheral neuropathy and pain on walking. Clin J Pain. 2015;31:946.","journal-title":"Clin J Pain"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00771-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-025-00771-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00771-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:04:43Z","timestamp":1763640283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-025-00771-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":165,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s40122-025-00771-1","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors, Yiming Wu, Xiaohui Guo, and Junqing Zhang declare no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}